Terms: = Breast cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Clinical Outcome
5 results:
1. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L
Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970
[TBL] [Abstract] [Full Text] [Related]
2. Expression levels of HER2/neu and those of collocated genes at 17q12-21, in breast cancer.
Glynn RW; Miller N; Mahon S; Kerin MJ
Oncol Rep; 2012 Jul; 28(1):365-9. PubMed ID: 22552811
[TBL] [Abstract] [Full Text] [Related]
3. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Labonte MJ; Wilson PM; Yang D; Zhang W; Ladner RD; Ning Y; Gerger A; Bohanes PO; Benhaim L; El-Khoueiry R; El-Khoueiry A; Lenz HJ
Ann Oncol; 2012 Jun; 23(6):1455-64. PubMed ID: 21989330
[TBL] [Abstract] [Full Text] [Related]
4. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract] [Full Text] [Related]
5. [Experiences with after care of patients with breast cancer].
Umbach GE; Holzki C; Perschmann U; Schnürch HG; Bender HG
Geburtshilfe Frauenheilkd; 1988 May; 48(5):292-8. PubMed ID: 3396831
[TBL] [Abstract] [Full Text] [Related]
